Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
2020 · The Lancet Oncology · 568 citations
https://doi.org/10.1016/s1470-2045(20)30110-8